| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|  | Check this box if no longer subject<br>to Section 16. Form 4 or Form 5<br>obligations may continue. See<br>Instruction 1(b). |
|--|------------------------------------------------------------------------------------------------------------------------------|
|--|------------------------------------------------------------------------------------------------------------------------------|

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

| 1. Name and Address of Reporting Feison                   |                                |                | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Aldeyra Therapeutics, Inc.</u> [ ALDX ] |                        | tionship of Reporting Po<br>all applicable)<br>Director                               | erson(s) to Issuer<br>10% Owner |
|-----------------------------------------------------------|--------------------------------|----------------|--------------------------------------------------------------------------------------------------|------------------------|---------------------------------------------------------------------------------------|---------------------------------|
| (Last) (First) (Middle)<br>C/O ALDEYRA THERAPEUTICS, INC. |                                | CS, INC.       | 3. Date of Earliest Transaction (Month/Day/Year)<br>03/16/2020                                   |                        | Officer (give title below)                                                            | Other (specify<br>below)        |
| 131 HARTWEI<br>(Street)<br>LEXINGTON<br>(City)            | L AVENUE, SUI<br>MA<br>(State) | 02421<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                         | 6. Indiv<br>Line)<br>X | ridual or Joint/Group Fili<br>Form filed by One Re<br>Form filed by More th<br>Person | porting Person                  |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code (Instr.<br>8) |   |        |               |        | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | (D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--------------------------------------------|-------------------------------------------------------------|-----------------------------------------|---|--------|---------------|--------|---------------------------------------------------------------------------|-----------------------------------|-------------------------------------------------------------------|
|                                 |                                            |                                                             | Code                                    | v | Amount | (A) or<br>(D) | Price  | Transaction(s)<br>(Instr. 3 and 4)                                        |                                   | (1130.4)                                                          |
| Common Stock                    | 03/16/2020                                 |                                                             | Р                                       |   | 40,000 | Α             | \$2.75 | 125,000                                                                   | D                                 |                                                                   |

|                                                     | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities) |                                            |                                                             |                              |   |     |     |                                                |                                                                                                     |       |                                                     |                                                                                                                            |                                                                          |                                                                    |  |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------|------------------------------|---|-----|-----|------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security                                                                          | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |     | 6. Date Exerc<br>Expiration Da<br>(Month/Day/Y | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr.<br>3 and 4) |       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|                                                     |                                                                                                                                                |                                            |                                                             | Code                         | v | (A) | (D) | Date<br>Exercisable                            | Expiration<br>Date                                                                                  | Title | Amount<br>or<br>Number<br>of<br>Shares              |                                                                                                                            |                                                                          |                                                                    |  |

#### Explanation of Responses:

**Remarks**:

### <u>/s/ Richard Douglas</u>

03/17/2020 Son Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\star$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.